Organon and Samsung Bioepis' HADLIMA granted FDA interchangeability designation approval for all high- and-low concentration presentations.

The Food and Drug Administration (FDA) has granted an expanded interchangeable designation for Yuflyma (adalimumab-aaty), now ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

Sales of AbbVie’s Humira (adalimumab) reached $4.4 billion for Europe at the end of June this year, according to healthcare data firm IQVIA. This represents a huge opportunity for companies ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

Humira (adalimumab), which is used to treat a range of inflammatory diseases including rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis will see its European patent expire ...

Humira (adalimumab) has potential interactions with other medications and certain vaccines. For example, Humira can interact with prednisone, warfarin, and live vaccines for measles, mumps ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

PR Newswire CHICAGO, May 23, 2025 CHICAGO Generic Pharmaceuticals Market size is projected to be valued at USD 391.5 billion in 2023 and r ...

such as adalimumab (Humira), golimumab (Simponi), and infliximab (Remicade) A medication called Janus kinase (JAK) inhibitors may also help reduce inflammation in certain types of arthritis.